Corundum Systems Biology
VC Fund
Corundum Systems Biology is a VC fund focused on Medical and Health Care. Corundum Systems Biology develops new businesses in the field of microbiome.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Corundum Systems Biology invests in
Stages Corundum Systems Biology invests in
Countries Corundum Systems Biology invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
4 more contacts available
Round size
- Seed
- $500k–$9M
Investment Focus
Industry
- Medical 2 (33%)
- Health Care 2 (33%)
- Pharmaceutical 2 (33%)
- Beauty 1 (17%)
- Women's 1 (17%)
Stage
- Seed 2 (33%)
- Grant 1 (17%)
- Series A 1 (17%)
- Series C 1 (17%)
Country
- United States 3 (50%)
- United Kingdom 1 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Caleb Bell
Venture Partner
|
Venture Partner | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SEQUENTIAL
|
Sequential Skin and Sequential Bio fall under the umbrella of Sequential: The Skin Microbiome Testing Co™Awarded the title "Most Significant" Testing Solution in the Industry - (Cosmetics & Toiletries, 2022), Sequential Bio is the skin microbiome company of the industry that specializes in microbiome testing and claimssubstantiation for brands formulating products for skin, scalp, vagina/vulva and oral care. Sequential offers a full end-to-end platform from study design, recruitment and testing, to analysis, and support on formulation development and certification. And it’s all done in vivo!Sequential Skin on the other hand is revolutionising skin health with the world's first consumer skin microbiome test. Formed of an award-winning team with a mission to empower individuals to make better-informed decisions about their skin health. (www.sequentialskin.com)Sequential is the product of the team's combined expertise in epigenetics, genetics, and microbiome research. Supported by Innovate UK, Enterprise SG, A*STAR, Genome Institute of Singapore, IndieBio New York, SOSV, Metaplanet, Scrum Ventures, CSB, and is a resident company of Johnson & Johnson Innovation – JLABS.Seen in Tatler, Cosmetic Designs, Tech Crunch, Genome Web, La Petite Journal, Global Wellness Summit, and Yahoo. | $3.5M / Seed / Mar 17, 2026 | |
Holobiome
|
Holobiome is an owner and operator of a therapeutic company intended to treat diseases of the enteric and central nervous systems. The company's platform delivers microbiome-based therapeutics to patients and the marketplace by treating depression, anxiety, and other mental health problems including our metabolism and the immune response,enabling patients to recover quickly from their diseases easily without any pain and suffering.Holobiome was established in 2015 and is based in Cambridge, Massachusetts. | $9M / Seed / Oct 09, 2024 | |
Freya Biosciences
|
Freya Biosciences is a clinical-stage women’s health company pioneering a new class of microbial immunotherapies. It is based in Copenhagen and Boston. | $38M / Series A / Dec 12, 2023 | |
|
SEQUENTIAL
|
Sequential Skin and Sequential Bio fall under the umbrella of Sequential: The Skin Microbiome Testing Co™Awarded the title "Most Significant" Testing Solution in the Industry - (Cosmetics & Toiletries, 2022), Sequential Bio is the skin microbiome company of the industry that specializes in microbiome testing and claimssubstantiation for brands formulating products for skin, scalp, vagina/vulva and oral care. Sequential offers a full end-to-end platform from study design, recruitment and testing, to analysis, and support on formulation development and certification. And it’s all done in vivo!Sequential Skin on the other hand is revolutionising skin health with the world's first consumer skin microbiome test. Formed of an award-winning team with a mission to empower individuals to make better-informed decisions about their skin health. (www.sequentialskin.com)Sequential is the product of the team's combined expertise in epigenetics, genetics, and microbiome research. Supported by Innovate UK, Enterprise SG, A*STAR, Genome Institute of Singapore, IndieBio New York, SOSV, Metaplanet, Scrum Ventures, CSB, and is a resident company of Johnson & Johnson Innovation – JLABS.Seen in Tatler, Cosmetic Designs, Tech Crunch, Genome Web, La Petite Journal, Global Wellness Summit, and Yahoo. | $500K / Seed / Sep 10, 2022 | |
|
Holobiome
|
Holobiome is an owner and operator of a therapeutic company intended to treat diseases of the enteric and central nervous systems. The company's platform delivers microbiome-based therapeutics to patients and the marketplace by treating depression, anxiety, and other mental health problems including our metabolism and the immune response,enabling patients to recover quickly from their diseases easily without any pain and suffering.Holobiome was established in 2015 and is based in Cambridge, Massachusetts. | $1M / Grant / Oct 28, 2021 | |
Vertero
|
Axial Therapeutics is a clinical stage biopharmaceutical company harnessing the gut-brain axis to develop novel Central Nervous System (CNS) Therapeutics to improve the quality of life for people with CNS diseases and disorders. | $37.3M / Series C / Oct 13, 2021 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Corundum Systems Biology invest in?
Corundum Systems Biology invests primarily in Medical, Health Care and Pharmaceutical startups, most often at Seed and Grant stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Corundum Systems Biology's check size?
Corundum Systems Biology typically joins rounds of $500k–$9M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Corundum Systems Biology participates in.
How do I contact Corundum Systems Biology?
Public channels for Corundum Systems Biology include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Corundum Systems Biology?
The team at Corundum Systems Biology includes Caleb Bell (Venture Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
